ArticleBMC infectious diseases2026
HIV risk and oral pre-exposure prophylaxis (PrEP) among people who inject drugs (PWID) in Nairobi: a cross-sectional study.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundPersons who inject drugs (PWID) in Kenya face a high HIV burden (18% prevalence). Although oral pre-exposure prophylaxis (PrEP) is effective for HIV prevention among PWID, its awareness and use remain low. This study assessed HIV acquisition risk, oral PrEP knowledge, and uptake among PWID in Nairobi, Kenya.
methodsHIV-negative PWID were recruited from four drop-in centers in Nairobi (February–March 2022). HIV risk from sexual and injection practices was measured using the National Drug and Alcohol Research Centre’s HIV Risk-Taking Behavior Scale (HRBS). Oral PrEP awareness and uptake were assessed using the Low PrEP Awareness and Use among PWID tool. Analyses included descriptive statistics, unpaired t-tests (HRBS scores), chi-square tests (PrEP awareness and use), logistic regression (factors associated with PrEP awareness), and Fisher’s exact tests (PrEP uptake), conducted in SPSS version 24.
findingsAmong 256 participants, 82.0% were male, 30.1% were on methadone, and 99.2% injected heroin. Mean HIV risk scores indicated moderate risk from injection practices (8.35/25) and sexual practices (11.59/30), totaling 19.94/55. HRBS scores were not associated with PrEP awareness (P = 0.493) or use (P = 0.727). Sexual HIV risk was higher among women than men (12.44/30 vs. 7.3/30; P < 0.001), and among those aged 18–24 versus 25–55 years (23.00/55 vs. 19.35/55; P = 0.016). PrEP awareness was 59.4%, but only 3.9% had ever used PrEP. Men were more likely than women to be aware of PrEP (84.8% vs. 53.8%; P < 0.001) and to have used it (13.0% vs. 1.9%; P < 0.001).
conclusionPWID in Nairobi have a moderate HIV risk, with young and female PWID disproportionately affected. Despite moderate awareness, PrEP uptake is very low. Targeted PrEP education, gender-responsive outreach, and integration of PrEP into harm reduction services are needed to improve uptake.
trial registrationClinicalTrials.gov Protocol Record STUDY0001370.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.